ASX & Press Releases

Friday, September 25, 2015

Alchemia Limited today announced that it has entered into a binding term sheet for the sale of the worldwide exclusive intellectual property rights to fondaparinux sodium, its generic anti-coagulant drug, to Dr Reddy's Laboratories.

Wednesday, September 2, 2015

Alchemia Limited today announces its financial results for the year ended 30 June 2015. The Group ended the 2015 financial year with net tangible assets (excluding deferred tax liabilities which relate to intangible assets) of $11.5 million (2014: $11.3 million).

Wednesday, September 2, 2015

Alchemia Limited release the Preliminary Final Report for the year ended 30 June 2015 - this report is provided to the ASX in accordance with listing rule 4.3A.

Friday, July 31, 2015

Alchemia reported a closing cash balance of $5.1m and a net operating cash outflow of $5.6m for the quarter ended 30 June 2015. This quarter's net cash burn includes close out of many contracts for the Phase III trial for HA-Irinotecan.

Friday, July 10, 2015

Alchemia Limited today announced the appointment of Mr Ken Poutakidis as interim Chairman of the Board of Directors.

Thursday, July 9, 2015

Alchemia announced the retirement of Mr Tim Hughes as Chairman and Non-Executive Director on the Board of Directors.

Monday, July 6, 2015

Alchemia Limited has received a Withdrawal of Requisition of General Meeting.

Friday, July 3, 2015
Alchemia Announces Assignment of VAST Technology

Alchemia announced today it has executed a deed of assignment to assign its VAST drug discovery technology (VAST) to VAST Biosciences Pty Ltd (VAST Biosciences).

Wednesday, July 1, 2015

Alchemia Limited has executed a binding term sheet for the sale of its 100% owned subsidiary, Alchemia Oncology Pty Ltd, with US biotechnology company, Panther Biotechnology Inc.

Friday, June 26, 2015

Alchemia announced the appointment of Mr Ken Poutakidis as a non-executive director on the Board of Directors on 26 June 2015.

Pages